XI'AN GLOBAL(002799)2024-05-22 12:34Group 1: Financial Performance and Debt Collection - The company has organized a specialized team for debt collection, which has not yet achieved substantial results [1][4] - The company will continue to follow up on accounts receivable collection and comply with regulatory disclosure obligations [4][5] - The company reported a revenue inflation of 1 billion in 2022 due to non-compliance with accounting standards [6] Group 2: Business Operations and Market Strategy - The subsidiary Lingkai Technology is currently operating normally, and the company is focusing on its core business [2][3] - The company is actively expanding into new markets and enhancing its investment in intelligent manufacturing for pharmaceutical packaging [5][6] - The company is developing high-end packaging solutions for various sectors, including cosmetics and healthcare products [5][6] Group 3: Regulatory Compliance and Corporate Governance - The company has established a special rectification working group to address regulatory inquiries and has completed necessary corrections [4][6] - The company emphasizes strict adherence to information disclosure obligations and will communicate any share repurchase plans in accordance with legal requirements [6][7] Group 4: Future Outlook and Development Plans - The company anticipates continued growth in demand for pharmaceutical and health consumer product packaging due to aging population trends [5] - Future development plans will be disclosed in the regular report scheduled for April 26, 2024 [6][7]